Table of Contents

1 Introduction (Page No. - 18)

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.3.1 Market Covered

1.3.2 Years Considered for the Study

1.4 Currency

1.5 Limitations

1.6 Stakeholders

2 Research Methodology (Page No. - 22)

2.1 Research Approach

2.1.1 Secondary Research

2.1.1.1 Key Data From Secondary Sources

2.1.2 Primary Research

2.1.2.1 Key Data From Primary Sources

2.1.2.2 Breakdown of Primaries

2.2 Market Size Estimation

2.3 Data Triangulation Approach

2.4 Market Share Analysis

2.5 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 32)

4.1 Vaccines Market Overview

4.2 North America: Vaccines Market, By Technology (2018)

4.3 Geographical Snapshot of the Vaccines Market

5 Market Overview (Page No. - 35)

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Prevalence of Infectious Diseases

5.2.1.2 Rising Focus on Immunization Programs

5.2.1.3 Growing Government Support for Vaccine Development

5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D

5.2.2 Restraints

5.2.2.1 High Cost of Vaccine Development

5.2.3 Opportunities

5.2.3.1 High Growth Prospects in Emerging Markets

5.2.3.2 Focus on Therapeutic Vaccines

5.2.3.3 Use of Adjuvants in Vaccines

5.2.4 Challenges

5.2.4.1 Inadequate Access to Vaccines

5.2.5 Burning Issues

5.2.5.1 Product Recalls

6 Industry Insights (Page No. - 42)

6.1 Regulatory Landscape

6.1.1 North America

6.1.2 Europe

6.1.3 Asia

6.1.4 RoW

6.2 Key Pipeline Products

6.3 New Vaccine Opportunities

6.3.1 HIV

6.3.1.1 HIV Vaccine: Product Pipeline

6.3.1.2 HIV Vaccine: Public-Private Initiatives

6.3.1.3 HIV Vaccine: Funding

6.3.2 Malaria

6.3.2.1 Malaria Vaccine: Product Pipeline

6.3.2.2 Malaria Vaccine: Public-Private Initiatives

6.3.3 Zika

6.3.3.1 Zika Vaccine: Product Pipeline

6.3.3.2 Zika Vaccine: Public-Private Initiatives

6.3.3.3 Zika Vaccine: Funding

6.3.4 Ebola

6.3.4.1 Ebola Vaccine: Product Pipeline

6.3.4.2 Ebola Vaccine: Public-Private Initiatives

6.3.4.3 Ebola Vaccine: Funding

6.3.4.4 Ebola projects funded by EC (2014�2020)

7 Vaccines Market, By Technology (Page No. - 56)

7.1 Introduction

7.2 Conjugate Vaccines

7.2.1 Conjugate Vaccines Hold the Largest Share of the Market

7.3 Inactivated & Subunit Vaccines

7.3.1 Ease of Storage and Transportation have Made Inactivated & Subunit Vaccines Popular

7.4 Live Attenuated Vaccines

7.4.1 Issues in Preserving and Maintaining Live Attenuated Vaccines has Slowed Market Growth

7.5 Recombinant Vaccines

7.5.1 Lack of Post-Vaccination Reactions and Reduced Need for Booster Doses are Driving R&D Into Recombinant Vaccines

7.6 Toxoid Vaccines

7.6.1 Company Initiatives and the Introduction of New Vaccines Will Support Market Growth

8 Vaccines Market, By Type (Page No. - 64)

8.1 Introduction

8.2 Monovalent Vaccines

8.2.1 in 2018, the Monovalent Vaccines Segment Accounted for the Largest Share of the Market

8.3 Multivalent Vaccines

8.3.1 Increasing Initiatives By Companies to Develop New Multivalent Vaccines is Driving the Growth of This Segment

9 Vaccines Market, By Disease Indication (Page No. - 68)

9.1 Introduction

9.2 Pneumococcal Disease

9.2.1 Pneumococcal Disease Segment Accounted for the Largest Share of the Market

9.3 DTP

9.3.1 Increasing Accessibility of DTP Vaccines in Developing Countries to Drive Market Growth

9.4 Influenza

9.4.1 Influenza Vaccines Segment to Grow at the Highest Rate During the Forecast Period

9.5 HPV

9.5.1 Growing Prevalence of HPV Infections to Support Market Growth

9.6 Meningococcal Disease

9.6.1 Rising Incidence of Meningococcal Disease to Support the Growth of This Market Segment

9.7 Polio

9.7.1 Government Initiatives to Support the Growth of This Market Segment

9.8 Hepatitis

9.8.1 High Prevalence of Hepatitis Infections is Driving the Demand for Immunization

9.9 Rotavirus

9.9.1 Rising Incidence of Rotavirus Infections to Drive Market Growth

9.10 MMR

9.10.1 Rising Incidence of Measles, Mumps, and Rubella Will Support the Growth of This Market Segment

9.11 Varicella

9.11.1 Promotion of Immunization Programs to Drive the Demand for Varicella Vaccines

9.12 Herpes Zoster

9.12.1 Herpes Zoster Vaccines to Witness Stable Demand During the Forecast Period

9.13 Other Disease Indications

10 Vaccines Market, By Route of Administration (Page No. - 85)

10.1 Introduction

10.2 Intramuscular and Subcutaneous Administration

10.2.1 Intramuscular and Subcutaneous Administration Accounted for the Largest Share of the Market

10.3 Oral Administration

10.3.1 Possibility of Irritation of the Gastric Mucosa May Limit the Growth of This Segment

10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type (Page No. - 90)

11.1 Introduction

11.2 Pediatric Patients

11.2.1 In 2018, the Pediatric Patients Segment Accounted for the Largest Share of the Market

11.3 Adult Patients

11.3.1 The Adult Patients Segment is Expected to Grow at the Highest CAGR During the Forecast Period

12 Vaccines Market, By Region (Page No. - 94)

12.1 Introduction

12.2 North America

12.2.1 US

12.2.1.1 The US is the Largest Market for Vaccines

12.2.2 Canada

12.2.2.1 High Incidence of Infectious Diseases is Driving the Demand for Vaccines in the Country

12.3 Europe

12.3.1 Germany

12.3.1.1 Significant Investments in R&D to Support Market Growth

12.3.2 UK

12.3.2.1 Launch of New Products to Support Market Growth in the UK in the Coming Years

12.3.3 France

12.3.3.1 Favorable Government Initiatives for Immunization to Support Market Growth in France

12.3.4 Italy

12.3.4.1 Conjugate Vaccines to Account for the Largest Share of the Italian Market

12.3.5 Spain

12.3.5.1 Rising Investments in Vaccine Development By Private Organizations to Support Market Growth in Spain

12.3.6 Rest of Europe

12.4 Asia

12.4.1 Japan

12.4.1.1 Government Initiatives for Increasing the Accessibility of Vaccines to Drive Market Growth in Japan

12.4.2 China

12.4.2.1 Growing Investments in the Biotechnology Sector to Drive Market Growth in China

12.4.3 India

12.4.3.1 Growth of the Biotechnology Sector and Development of New Vaccines to Support Market Growth in India

12.4.4 Rest of Asia

12.5 Rest of the World

12.5.1 Latin America

12.5.2 Other RoW Countries

13 Competitive Landscape (Page No. - 125)

13.1 Overview

13.2 Market Share Analysis

13.3 Competitive Leadership Mapping (Overall Market)

13.3.1 Visionary Leaders

13.3.2 Innovators

13.3.3 Dynamic Differentiators

13.3.4 Emerging Companies

13.4 Competitive Situation and Trends

13.4.1 Agreements, Contracts, and Collaborations

13.4.2 Product Launches and Approvals

13.4.3 Acquisitions

13.4.4 Expansions

14 Company Profiles (Page No. - 132)

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

14.1 Glaxosmithkline PLC

14.2 Pfizer, Inc

14.3 Merck & Co., Inc

14.4 Sanofi Pasteur SA

14.5 CSL Limited

14.6 Emergent Biosolutions, Inc

14.7 Johnson & Johnson

14.8 Astrazeneca

14.9 Serum Institute of India Pvt., LTD

14.10 Bavarian Nordic

14.11 Mitsubishi Tanabe Pharma Corporation

14.12 Daiichi Sankyo Company, Limited

14.13 Panacea Biotec, LTD

14.14 Biological E

14.15 Bharat Biotech

14.16 Other Companies

14.16.1 Sinovac Biotech, LTD

14.16.2 Incepta Vaccine, LTD

14.16.3 Valneva SE

14.16.4 VBI Vaccines Inc

14.16.5 PT Bio Farma (Persero)

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

15 Appendix (Page No. - 179)

15.1 Discussion Guide

15.2 Knowledge Store: Marketsandmarkets� Subscription Portal

15.3 Available Customizations

15.4 Related Reports

15.5 Author Details



List of Tables (107 Tables)

Table 1 Incidence of Infectious Diseases

Table 2 NIH Funding for Vaccine Research, 2013�2018 (USD Million)

Table 3 Immunization Coverage, By Disease, 2016 vs 2018

Table 4 Regulatory Authorities in Europe

Table 5 Regulatory Authorities in Asia

Table 6 Key Pipeline Vaccines

Table 7 Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 8 Cost of Meningococcal Conjugate Vaccines for Pediatric Patients

Table 9 Cost of Meningococcal Conjugate Vaccines for Adult Patients

Table 10 Conjugate Vaccines Market, By Region, 2017�2024 (USD Million)

Table 11 Examples of Inactivated & Subunit Vaccines

Table 12 Inactivated & Subunit Vaccines Market, By Region, 2017�2024 (USD Million)

Table 13 Live Attenuated Vaccines Market, By Region, 2017�2024 (USD Million)

Table 14 Examples of Recombinant Vaccines

Table 15 Recombinant Vaccines Market, By Region, 2017�2024 (USD Million)

Table 16 Toxoid Vaccines Market, By Region, 2017�2024 (USD Million)

Table 17 Vaccines Market, By Type, 2017�2024 (USD Million)

Table 18 Monovalent Vaccines Market, By Region, 2017�2024 (USD Million)

Table 19 Examples of Notable Multivalent Vaccines Available in the Market

Table 20 Multivalent Vaccines Market, By Region, 2017�2024 (USD Million)

Table 21 Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 22 List of Commercially Available Pneumococcal Vaccines in the Market

Table 23 Vaccines Market for Pneumococcal Disease, By Region, 2017�2024 (USD Million)

Table 24 List of Commercially Available DTP Vaccines in the Market

Table 25 Vaccines Market for DTP, By Region, 2017�2024 (USD Million)

Table 26 List of Commercially Available Influenza Vaccines in the Market

Table 27 Vaccines Market for Influenza, By Region, 2017�2024 (USD Million)

Table 28 List of Commercially Available HPV Vaccines in the Market

Table 29 Vaccines Market for HPV, By Region, 2017�2024 (USD Million)

Table 30 List of Commercially Available Meningococcal Disease Vaccines in the Market

Table 31 Vaccines Market for Meningococcal Disease, By Region, 2017�2024 (USD Million)

Table 32 List of Commercially Available Polio Vaccines in the Market

Table 33 Vaccines Market for Polio, By Region, 2017�2024 (USD Million)

Table 34 List of Commercially Available Hepatitis Vaccines in the Market

Table 35 Vaccines Market for Hepatitis, By Region, 2017�2024 (USD Million)

Table 36 List of Commercially Available Rotavirus Vaccines in the Market

Table 37 Vaccines Market for Rotavirus, By Region, 2017�2024 (USD Million)

Table 38 List of Commercially Available MMR Vaccines in the Market

Table 39 Vaccines Market for MMR, By Region, 2017�2024 (USD Million)

Table 40 List of Commercially Available Varicella Vaccines in the Market

Table 41 Vaccines Market for Varicella, By Region, 2017�2024 (USD Million)

Table 42 Vaccines Market for Herpes Zoster, By Region, 2017�2024 (USD Million)

Table 43 List of Commercially Available Vaccines for Other Disease Indications

Table 44 Vaccines Market for Other Disease Indications, By Region, 2017�2024 (USD Million)

Table 45 Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 46 Advantages and Disadvantages of Intramuscular and Subcutaneous Administration

Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2017�2024 (USD Million)

Table 48 Vaccines Market for Oral Administration, By Region, 2017�2024 (USD Million)

Table 49 Vaccines Market for Other Routes of Administration, By Region, 2017�2024 (USD Million)

Table 50 Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 51 Vaccines Market for Pediatric Patients, By Region, 2017�2024 (USD Million)

Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 2017�2024 (USD Million)

Table 53 Vaccines Market for Adult Patients, By Region, 2017�2024 (USD Million)

Table 54 North America: Vaccines Market for Adult Patients, By Country, 2017�2024 (USD Million)

Table 55 Vaccines Market, By Region, 2017�2024 (USD Million)

Table 56 North America: Vaccines Market, By Country, 2017�2024 (USD Million)

Table 57 North America: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 58 North America: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 59 North America: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 60 North America: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 61 North America: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 62 Number of New Infectious Disease Cases in the Us, 2017

Table 63 US: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 64 US: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 65 Number of New Infectious Disease Cases in Canada

Table 66 Canada: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 67 Canada: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 68 Europe: Vaccines Market, By Country, 2017�2024 (USD Million)

Table 69 Europe: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 70 Europe: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 71 Europe: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 72 Europe: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 73 Europe: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 74 Germany: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 75 UK: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 76 France: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 77 Italy: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 78 Spain: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 79 RoE: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 80 Asia: Health Expenditure Per Capita, By Country, 2000, 2014, and 2016 (USD)

Table 81 Asia: Vaccines Market, By Country, 2017�2024 (USD Million)

Table 82 Asia: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 83 Asia: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 84 Asia: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 85 Asia: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 86 Asia: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 87 Disease Incidence in Japan, 2016�2018

Table 88 Japan: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 89 China: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 90 India: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 91 RoA: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 92 RoW: Vaccines Market, By Region, 2017�2024 (USD Million)

Table 93 RoW: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 94 RoW: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 95 RoW: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 96 RoW: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 97 RoW: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 98 Latin America: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 99 Latin America: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 100 Latin America: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 101 Latin America: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 102 Latin America: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

Table 103 Other RoW Countries: Vaccines Market, By Technology, 2017�2024 (USD Million)

Table 104 Other RoW Countries: Vaccines Market, By Type, 2017�2024 (USD Million)

Table 105 Other RoW Countries: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)

Table 106 Other RoW Countries: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)

Table 107 Other RoW Countries: Vaccines Market, By Patient Type, 2017�2024 (USD Million)



List of Figures (35 Figures)

Figure 1 Vaccines Market Segmentation

Figure 2 Research Design

Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region

Figure 4 Bottom-Up Approach

Figure 5 Top-Down Approach

Figure 6 Data Triangulation Methodology

Figure 7 Vaccines Market, By Technology, 2019 vs 2024 (USD Million)

Figure 8 Vaccines Market, By Type, 2019 vs 2024 (USD Million)

Figure 9 Vaccines Market, By Disease Indication, 2019 vs 2024 (USD Million)

Figure 10 Vaccines Market, By Route of Administration, 2019 vs 2024 (USD Million)

Figure 11 Vaccines Market, By Patient Type, 2019 vs 2024 (USD Million)

Figure 12 Geographical Snapshot of the Vaccines Market

Figure 13 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth

Figure 14 Conjugate Vaccines Accounted for the Largest Share of the North American Vaccines Market in 2018

Figure 15 Asia to Witness the Highest Growth in the Vaccines Market From 2019 to 2024

Figure 16 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges

Figure 17 Regulatory Approval Process for Vaccines

Figure 18 North America Will Continue to Dominate the Vaccines Market in 2024

Figure 19 North America: Vaccines Market Snapshot

Figure 20 Europe: Vaccines Market Snapshot

Figure 21 Asia: Vaccines Market Snapshot

Figure 22 Vaccines Market Share Analysis, By Key Player, 2018 127

Figure 23 Competitive Leadership Mapping: Vaccines Market 130

Figure 24 Glaxosmithkline PLC.: Company Snapshot (2018)

Figure 25 Pfizer, Inc.: Company Snapshot (2018)

Figure 26 Merck & Co., Inc.: Company Snapshot (2018)

Figure 27 Sanofi Pasteur SA: Company Snapshot (2018)

Figure 28 CSL Limited: Company Snapshot (2018)

Figure 29 Emergent Biosolutions, Inc.: Company Snapshot (2018)

Figure 30 Johnson & Johnson: Company Snapshot (2018)

Figure 31 Astrazeneca: Company Snapshot (2018)

Figure 32 Bavarian Nordic: Company Snapshot (2018)

Figure 33 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2018)

Figure 34 Daiichi Sankyo Company: Company Snapshot (2018)

Figure 35 Panacea Biotec: Company Snapshot (2018)

